UMR and Zepbound: The Self-Funded Plan Administrator Question

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · As of May 2026, confirm directly with your plan

Key Takeaways

• UMR is not an insurance company; it is a third-party administrator for self-funded employer plans
• Your employer designs Zepbound coverage; UMR administers the benefit your employer chose
• Many UMR-administered plans exclude anti-obesity medications as a category
• UMR typically routes pharmacy benefit administration through OptumRx
• The December 2024 OSA indication may provide an alternative pathway in plans that exclude obesity drugs

Direct answer

Whether UMR covers Zepbound depends entirely on your employer's plan design, not on UMR. UMR is a third-party administrator that processes claims and manages benefits for self-funded employer plans. Each employer designs its own coverage, including whether anti-obesity medications are covered. The first step is reading your Summary Plan Description to determine what your specific plan covers.

Table of contents

1. What UMR actually is
2. Why this is different from being a fully insured plan member
3. How to find your specific plan's Zepbound coverage
4. The UMR-OptumRx relationship
5. Common UMR PA criteria when Zepbound is covered
6. The OSA pathway as a coverage alternative
7. Cost scenarios across UMR plan designs
8. What happens when your employer excludes anti-obesity drugs
9. Appealing a UMR denial
10. HR advocacy as an underused strategy
11. Decision framework
12. FAQ
13. Sources

What UMR actually is

UMR is United Medical Resources, a third-party administrator (TPA) subsidiary of UnitedHealthcare. The company processes claims, manages prior authorizations, provides member services, and operates customer-facing infrastructure for self-funded employer plans.

The critical distinction: UMR is not an insurance company. UMR does not bear financial risk for the cost of member care. The employer does. UMR provides administrative services under contract with the employer, processing claims per the benefit design the employer chose.

This distinction has practical implications:

• UMR cannot expand coverage beyond what the employer's plan allows
• UMR cannot exclude coverage that the employer's plan includes
• The benefit design is determined by the employer, not by UMR
• Two different employers using UMR can have completely different Zepbound coverage

Why this is different from being a fully insured plan member

A member of a fully insured commercial UnitedHealthcare plan has UnitedHealthcare as the insurer bearing risk. UnitedHealthcare's standard formulary applies, with employer customization typically limited to plan tier choices. Coverage decisions follow UnitedHealthcare's clinical criteria.

A member of a self-funded plan administered by UMR has their employer as the financial backer. The employer designed the benefit. The Summary Plan Description spells out what is and is not covered. UMR processes claims and PAs against the employer's specification.

ERISA governs self-funded employer plans. Federal preemption means state insurance mandates often do not apply. An employer can design a plan that excludes anti-obesity drugs even in states that mandate coverage for fully insured plans.

How to find your specific plan's Zepbound coverage

To determine your Zepbound coverage status:

1. Read your Summary Plan Description (SPD). Search for "anti-obesity," "weight loss," or "GLP-1" exclusions. The SPD is the legal document defining your benefit
2. Log in to umr.com and use the medication lookup tool
3. Call UMR member services using the number on your insurance card
4. Ask your employer's HR or benefits team. They have full visibility into the plan design
5. Review your plan's pharmacy formulary (typically administered by OptumRx)

HR can often answer faster than UMR member services because they have direct access to the plan design documents. UMR member services has to look up your specific group/plan in their administrative system.

The UMR-OptumRx relationship

UMR is part of UnitedHealth Group's broader services arm. Pharmacy benefit administration for UMR-administered plans typically runs through OptumRx, the UnitedHealth Group PBM.

This creates a multi-entity workflow:

• Employer designs the plan benefit
• UMR administers medical claims and serves as TPA
• OptumRx administers pharmacy benefits, processes PAs for medications including Zepbound
• Network pharmacies fulfill covered prescriptions

Some employers using UMR for medical claims contract separately with a different PBM (Express Scripts, Caremark, or smaller PBMs) for pharmacy benefits. Check your specific plan documentation for the actual PBM administering your pharmacy benefit.

Common UMR PA criteria when Zepbound is covered

When the underlying employer plan covers anti-obesity drugs and Zepbound is on formulary, PA typically requires:

1. BMI 30 or higher, or BMI 27 with comorbidity
2. Structured weight-management program participation (3 to 6 months typical)
3. Absence of contraindications (MTC history, MEN 2)
4. Documentation of medical necessity
5. Step therapy in some plans

For the OSA indication:

• Polysomnography confirming moderate-to-severe OSA
• BMI 30 or higher
• CPAP intolerance, insufficiency, or contraindication

Initial approval is typically 6 months with reauthorization requiring documented clinical response.

The OSA pathway as a coverage alternative

The December 2024 FDA approval of tirzepatide for moderate-to-severe obstructive sleep apnea created a parallel coverage pathway. For UMR-administered plans that exclude anti-obesity medications, the OSA indication may still produce coverage because sleep medicine is typically a covered category even when obesity drugs are excluded.

The SURMOUNT-OSA trials (Malhotra et al., New England Journal of Medicine 2024) demonstrated substantial AHI reduction with tirzepatide in patients with confirmed OSA and obesity. Many patients moved from severe to mild OSA classification by week 52.

For UMR members with diagnosed moderate-to-severe OSA, pursuing the OSA indication separately from obesity is often more productive than appealing under an obesity-only request.

Cost scenarios across UMR plan designs

Plan design scenario	Approximate monthly Zepbound cost
Employer covers anti-obesity drugs, tier 3	$50 to $100
Employer covers anti-obesity drugs, specialty tier	$100 to $200
Employer excludes anti-obesity drugs entirely	Not covered; full cash price
OSA indication covered (sleep medicine)	$50 to $200 depending on tier
Uncovered retail cash	Approximately $1,000
LillyDirect vial program 2.5 mg	Approximately $349
LillyDirect vial program 5 mg	Approximately $499

What happens when your employer excludes anti-obesity drugs

Many self-funded employer plans administered by UMR exclude anti-obesity medications. Common reasons employers cite:

• Per-member-per-month budget impact of GLP-1 coverage
• High turnover populations where the employer does not retain members long enough to capture long-term savings
• Actuarial cost-benefit analyses showing high near-term spend
• Plan design history (some plans have excluded weight-loss drugs for decades)

If your plan excludes anti-obesity drugs:

• Prior authorization will not produce coverage
• Appeals citing medical necessity will typically not succeed because the exclusion is categorical, not necessity-based
• The OSA indication may provide an alternative if you have moderate-to-severe OSA
• The cardiovascular indication for Wegovy may apply if you have established heart disease
• HR advocacy and benefit redesign during open enrollment may be your best long-term path

Appealing a UMR denial

UMR processes appeals on behalf of self-funded plans. The appeal pathway:

1. Internal first-level appeal: UMR clinical review with additional documentation
2. Internal second-level appeal: independent clinical review if available under plan terms
3. External review: ERISA self-funded plans do not always have state IRO access; federal review under ERISA applies
4. Federal court action under ERISA section 502(a)(1)(B) as a final option

The standard for ERISA appeals is "arbitrary and capricious" review by federal courts, which is highly deferential to the plan administrator's decision. Coverage exclusions written into the SPD are very difficult to challenge in court.

Medical necessity appeals can sometimes succeed when the underlying plan covers the drug class but denied a specific request. Exclusion-based denials are much harder to overcome through appeals.

HR advocacy as an underused strategy

For UMR members in plans that exclude anti-obesity drugs, advocacy with HR or your benefits team may produce more meaningful change than individual appeals. Self-funded employer plans can be redesigned during open enrollment cycles.

Employer benefits decisions are influenced by:

• Employee surveys and benefit utilization data
• Competing employer benefit packages in your industry
• Total cost of care analyses showing downstream value
• HR's perception of employee priorities

Some employers have added GLP-1 coverage in 2024-2025 in response to coordinated employee advocacy. Trade publications report a slow but real expansion of obesity drug coverage in benefit plans. Your voice matters in this conversation.

Decision framework

If your UMR-administered plan covers anti-obesity drugs: Submit standard PA. Document BMI, comorbidities, weight-management program participation.

If your plan excludes anti-obesity drugs: Read the exclusion language carefully. If you have moderate-to-severe OSA, pursue the OSA indication separately. If you have established heart disease, consider Wegovy under the CV indication.

If you have OSA confirmed by sleep study: The OSA pathway often produces coverage even in plans that exclude obesity drugs. Pursue this through sleep medicine.

If you need out-of-pocket options: LillyDirect's vial program at $349 to $499 is substantially below retail cash price.

If you want long-term coverage change: Engage HR about benefit design during open enrollment. Coordinated employee voice has produced real coverage expansions at some employers.

FAQ

Does UMR cover Zepbound? UMR doesn't design coverage. Your employer does. Coverage depends entirely on your plan design.

What is UMR? Third-party administrator subsidiary of UnitedHealthcare for self-funded employer plans.

How do I find out if my UMR plan covers Zepbound? Check SPD, umr.com, member services, or HR.

What PBM does UMR use? Typically OptumRx; sometimes employer-contracted alternatives.

How much does Zepbound cost with UMR? If covered: $50 to $200. If excluded: full cash price.

Can I appeal a UMR denial? Yes, but exclusion-based denials are very difficult to overcome.

What if my employer plan excludes Zepbound? Pursue OSA pathway if applicable, LillyDirect for out-of-pocket, HR advocacy for benefit change.

Does the OSA indication help with UMR coverage? Often yes, even in plans excluding obesity drugs.

Sources

1. FDA, Zepbound (tirzepatide) prescribing information, OSA label expansion, December 2024
2. Malhotra A et al. Tirzepatide for Obstructive Sleep Apnea (SURMOUNT-OSA). New England Journal of Medicine. June 2024
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022
4. UMR plan administration materials and member resources, 2026
5. OptumRx Standard Formulary, 2026 plan year
6. ERISA section 502(a)(1)(B) federal court review standards
7. Department of Labor ERISA appeals procedures, EBSA guidance
8. Kaiser Family Foundation, Employer Health Benefits Survey, 2024 edition
9. Eli Lilly, LillyDirect Zepbound self-pay vial program, 2025-2026
10. Mercer National Survey of Employer-Sponsored Health Plans, obesity benefit trends 2024-2025
11. American Academy of Sleep Medicine, OSA Clinical Practice Guidelines, 2023 update

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with licensed clinicians and 503A compounding pharmacy partners. FormBlends has no commercial relationship with UMR, UnitedHealth Group, OptumRx, or Eli Lilly. Plan administration descriptions reflect publicly available information as of May 2026.

Compounded Medication Notice. Compounded tirzepatide prepared by 503A pharmacies is a different product than FDA-approved Zepbound. Compounded preparations are not FDA-approved and are not therapeutically equivalent to brand-name tirzepatide.

Results Disclaimer. Clinical trial outcomes including weight loss and AHI reduction reflect average effects in study populations. Individual results vary by dose tolerability, adherence, and baseline metabolic status.

Trademark Notice. Zepbound is a registered trademark of Eli Lilly and Company. UMR is a registered service mark of United Medical Resources, a subsidiary of UnitedHealthcare. OptumRx and UnitedHealthcare are registered marks of UnitedHealth Group Incorporated. References are informational.